Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Guo J, et al. Among authors: bastian bc. Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079. Ann Oncol. 2017. PMID: 28327988 Free PMC article. Clinical Trial.
Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA, Busam K, Pinkel D, Bastian BC. Curtin JA, et al. Among authors: bastian bc. J Clin Oncol. 2006 Sep 10;24(26):4340-6. doi: 10.1200/JCO.2006.06.2984. Epub 2006 Aug 14. J Clin Oncol. 2006. PMID: 16908931
KIT as a therapeutic target in melanoma.
Garrido MC, Bastian BC. Garrido MC, et al. Among authors: bastian bc. J Invest Dermatol. 2010 Jan;130(1):20-7. doi: 10.1038/jid.2009.334. J Invest Dermatol. 2010. PMID: 19847190 Free PMC article.
Mutation-driven drug development in melanoma.
Flaherty KT, Hodi FS, Bastian BC. Flaherty KT, et al. Among authors: bastian bc. Curr Opin Oncol. 2010 May;22(3):178-83. doi: 10.1097/cco.0b013e32833888ee. Curr Opin Oncol. 2010. PMID: 20401974 Free PMC article. Review.
Genetic and morphologic features for melanoma classification.
Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, Scolyer RA, Spatz A, Bastian BC. Broekaert SM, et al. Among authors: bastian bc. Pigment Cell Melanoma Res. 2010 Dec;23(6):763-70. doi: 10.1111/j.1755-148X.2010.00778.x. Pigment Cell Melanoma Res. 2010. PMID: 20874733 Free PMC article.
KIT as a therapeutic target in metastatic melanoma.
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. Carvajal RD, et al. Among authors: bastian bc. JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746. JAMA. 2011. PMID: 21642685 Free PMC article. Clinical Trial.
Beyond BRAF in melanoma.
Daud A, Bastian BC. Daud A, et al. Among authors: bastian bc. Curr Top Microbiol Immunol. 2012;355:99-117. doi: 10.1007/82_2011_163. Curr Top Microbiol Immunol. 2012. PMID: 21826607 Review.
Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Minor DR, et al. Among authors: bastian bc. Clin Cancer Res. 2012 Mar 1;18(5):1457-63. doi: 10.1158/1078-0432.CCR-11-1987. Epub 2012 Jan 18. Clin Cancer Res. 2012. PMID: 22261812
234 results